Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)

Overview

Journal Pharmacoecon Open

Date 2023 Nov 18

PMID 37980316

Authors

Hilary M DuBrock

Hayley D Germack

Marjolaine Gauthier-Loiselle

Jorg Linder

Ambika Satija

Ameur M Manceur

Martin Cloutier

Patrick Lefebvre

Sumeet Panjabi

Robert P Frantz

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to assess health care resource utilization (HRU) and costs associated with delayed pulmonary arterial hypertension (PAH) diagnosis in the United States.

Methods: Eligible adults with newly diagnosed PAH from Optum's de-identified Clinformatics Data Mart Database (2016-2021) were assigned to mutually exclusive cohorts based on time between first PAH-related symptom and first PAH diagnosis (i.e., ≤12 months' delay, >12 to ≤24 months' delay, >24 months' delay). All-cause HRU and health care costs per patient per month (PPPM) were assessed during the first year following diagnosis and compared across cohorts using regression analysis adjusted for baseline covariates. Sensitivity analyses were conducted to assess outcomes during all available follow-up post-diagnosis.

Results: Among 538 patients (mean age: 65.6 years; 60.6% female), 60.8% had ≤12 months' delay, 23.4% had a delay of >12 to ≤24 months, and 15.8% had >24 months' delay. Compared with ≤12 months, delays of >12 to ≤24 months and >24 months were associated with increased hospitalizations (incidence rate ratio [95% confidence interval]: 1.40 [1.11-1.71] vs 1.71 [1.29-2.12]) and outpatient visits (1.17 [1.06-1.30] vs 1.26 [1.08-1.41]). Longer delays were also associated with more intensive care unit (ICU) stays and 30-day readmissions. Diagnosis delays translated into excess costs PPPM of US$3986 [1439-6436] for >12 to ≤24 months and US$5366 [2107-8524] for >24 months compared with ≤12 months' delay; increased hospitalization costs (US$3248 [1108-5135] and US$4048 [1401-6342], respectively) being the driver. Sensitivity analyses yielded similar trends.

Conclusions: Delayed PAH diagnosis is associated with significant incremental economic burden post-diagnosis, driven by hospitalizations including ICU stays and 30-day readmissions, highlighting the need for increased awareness and a potential benefit of earlier screening.

References

Leber L, Beaudet A, Muller A . Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021; 11(1):2045894020977300. PMC: 7797595. DOI: 10.1177/2045894020977300. View

Frost A, Badesch D, Barst R, Benza R, Elliott C, Farber H . The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2010; 139(1):128-37. DOI: 10.1378/chest.10-0075. View

Thenappan T, Ormiston M, Ryan J, Archer S . Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018; 360:j5492. PMC: 6889979. DOI: 10.1136/bmj.j5492. View

Burger C, Ghandour M, Padmanabhan Menon D, Helmi H, Benza R . Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. Clinicoecon Outcomes Res. 2017; 9:731-739. PMC: 5703162. DOI: 10.2147/CEOR.S119117. View

Burgoyne D . Reducing economic burden and improving quality of life in pulmonary arterial hypertension. Am J Manag Care. 2021; 27(3 Suppl):S53-S58. DOI: 10.37765/ajmc.2021.88611. View

Khou V, Anderson J, Strange G, Corrigan C, Collins N, Celermajer D . Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry. Respirology. 2020; 25(8):863-871. DOI: 10.1111/resp.13768. View

Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S . Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: The delay study. Pulm Circ. 2013; 3(1):89-94. PMC: 3641745. DOI: 10.4103/2045-8932.109919. View

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173(9):1023-30. DOI: 10.1164/rccm.200510-1668OC. View

Badesch D, Raskob G, Elliott C, Krichman A, Farber H, Frost A . Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2009; 137(2):376-87. DOI: 10.1378/chest.09-1140. View

10.

Brown L, Chen H, Halpern S, Taichman D, McGoon M, Farber H . Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011; 140(1):19-26. PMC: 3198486. DOI: 10.1378/chest.10-1166. View

11.

Zanatta E, Polito P, Famoso G, Larosa M, De Zorzi E, Scarpieri E . Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. Exp Biol Med (Maywood). 2019; 244(2):120-131. PMC: 6405825. DOI: 10.1177/1535370218824101. View

12.

Studer S, Kingman M, Calo L, Cannon H, Dunn J, James 3rd T . Considerations for optimal management of patients with pulmonary arterial hypertension: a multi-stakeholder roundtable discussion. Am J Manag Care. 2017; 23(6 Suppl):S95-S104. View

13.

Quan H, Li B, Couris C, Fushimi K, Graham P, Hider P . Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011; 173(6):676-82. DOI: 10.1093/aje/kwq433. View

14.

Didden E, Lee E, Wyckmans J, Quinn D, Perchenet L . Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data. Pulm Circ. 2023; 13(1):e12188. PMC: 9843478. DOI: 10.1002/pul2.12188. View

15.

Studer S, Hull M, Pruett J, Koep E, Tsang Y, Drake 3rd W . Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database. Pulm Circ. 2018; 9(1):2045894018816294. PMC: 6432690. DOI: 10.1177/2045894018816294. View

16.

Ogbomo A, Tsang Y, Mallampati R, Panjabi S . The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States. J Manag Care Spec Pharm. 2022; 28(6):608-616. PMC: 10372985. DOI: 10.18553/jmcp.2022.28.6.608. View

17.

Sikirica M, Iorga S, Bancroft T, Potash J . The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014; 14:676. PMC: 4301626. DOI: 10.1186/s12913-014-0676-0. View

18.

Pizzicato L, Nadipelli V, Governor S, Mao J, Lanes S, Butler J . Real-world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States. Pulm Circ. 2022; 12(2):e12090. PMC: 9248786. DOI: 10.1002/pul2.12090. View

19.

Burke J, Hunsche E, Regulier E, Nagao M, Buzinec P, Iii W . Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. Am J Manag Care. 2015; 21(3 Suppl):s47-58. View

20.

Burger C, Long P, Shah M, McGoon M, Miller D, Romero A . Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014; 146(5):1263-1273. PMC: 4219341. DOI: 10.1378/chest.14-0193. View